Protuoso Biosciences raises US$9.5 million to advance multifunctional biologics

The seed funding for Protuoso Biosciences, with leadership from Taiwanese VC firms, illustrates how capital from Asia is flowing into US-based biotech startups. This investment supports Protuoso's strategy of using computational protein design, synthetic biology, and AI-enabled engineering to develop 'Muxbodies.' These are designed to combine various protein components into a single molecule to engage multiple biological mechanisms, potentially addressing complex diseases more effectively than single-target therapies.

Protuoso's Muxbody platform aims to create therapies that can both activate and inhibit biological activities, tailoring treatments to diseases involving interconnected pathways. The company's 'hub-and-spoke' business model is designed to generate multiple drug candidates from this core platform. This approach allows for independent development, partnerships, or spin-outs, suggesting a diversified strategy for commercializing its therapeutic programs.

The company's pipeline includes therapies for obesity and related organ damage within cardiometabolic diseases, next-generation immune cell engagers for solid tumors, and expanded research into autoimmune conditions. Christopher Shen of Taya Venture noted the combination of platform technology, an experienced team, and a pathway to clinical development as factors making Protuoso an attractive early-stage investment.